Accéder au contenu
Merck

Exostosin 1 regulates cancer cell stemness in doxorubicin-resistant breast cancer cells.

Oncotarget (2017-10-21)
Sarala Manandhar, Chang-Gu Kim, Sun-Hee Lee, Soo Hyun Kang, Nikita Basnet, You Mie Lee
RÉSUMÉ

Cancer stem cells (CSCs) are associated with cancer recurrence following radio/chemotherapy owing to their high resistance to therapeutic intervention. In this study, we investigated the role of exostoxin 1 (EXT1), an endoplasmic reticulum (ER)-residing type II transmembrane glycoprotein, in cancer cell stemness. DNA microarray analysis revealed that doxorubicin-resistant MCF7/ADR cells have high levels of EXT1 expression compared to its parental cell line, MCF7. These cells showed significantly higher populations of CSCs and larger populations of aldehyde dehydrogenase (ALDH

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Suplatast tosylate, ≥98% (HPLC)
Sigma-Aldrich
MISSION® esiRNA, targeting human EXT1